Immunicum AB (IMMU) Stock Statistics & Valuation Metrics

Immunicum AB has a market cap or net worth of kr301.88M. The enterprise value is kr210.73M.

Immunicum AB has 62,584,580 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immunicum AB’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -19.91%.

The current PE Ratio of Immunicum AB is ―. Immunicum AB’s PEG ratio is 0.14.

In the last 12 months, Immunicum AB had revenue of 0.00 and earned -113.26M in profits. Earnings per share was -2.17.

In the last 12 months, operating cash flow was -81.53M and capital expenditures -307.00K, giving a free cash flow of -81.84M billion.

Immunicum AB pays an annual dividend of ―, resulting in a dividend yield of ―

Immunicum AB upcoming earnings date is May 8, 2026, Before Open (Confirmed).

Immunicum AB as a current ratio of 2.70, with Debt / Equity ratio of 5.69%

In the past 12 months, Immunicum AB has paid 0.00 in taxes.

Immunicum AB EV to EBITDA ratio is -2.17, with an EV/FCF ratio of -3.19.

Immunicum AB has kr64.66M in cash and marketable securities with kr33.28M in debt, giving a net cash position of kr31.37M billion.

Gross margin is -133.28%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Immunicum AB is ―, which is 11.43% higher than the current price. The consensus rating is ―